EFFICACY OF PIRLINDOLE, A HIGHLY SELECTIVE REVERSIBLE INHIBITOR OF MONOAMINE-OXIDASE TYPE-A, IN THE PREVENTION OF EXPERIMENTALLY INDUCED EPILEPTIC SEIZURES

被引：18

作者：

MEDVEDEV, A

GORKIN, V

SHVEDOV, V

FEDOTOVA, O

FEDOTOVA, I

SEMIOKHINA, A

机构：

[1] Institute of Biological and Medical Chemistry, Academy of Medical Sciences, Moscow, 119832 GSP

[2] Centre of Drug Chemistry, The All-Union Institute of Pharmaceutical Chemistry, Moscow

[3] Biological Faculty, MV Lomonosov State University, Moscow

来源：

DRUG INVESTIGATION | 1992年 / 4卷 / 06期

关键词：

D O I：

10.1007/BF03259215

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Intraperitoneal administration of pirlindole (pirazidole) or 'soluble pirlindole' 50 mg/kg bodyweight prolonged the onset of seizures and decreased the intensity of seizures in rats genetically selected for high sensitivity to audiogenic hereditary epilepsy [Krushinsky-Molodkina (KM) rats]. In this experimental model of epilepsy, pirlindole prevented qualitative alteration (transformation) in the catalytic activity of membrane-bound type A monoamine oxidases (MAO-A), pathogenetically important for the development of the audiogenic seizures. Modification of the enzymatic properties of the monoamine oxidases causes an increase in gamma-aminobutyric acid (GABA) deamination in the mitochondrial fraction of the brain. The data obtained suggest that selective inhibitors of MAO-A, such as pirlindole, may prevent experimental epileptic seizures.

引用

页码：501 / 507

页数：7

共 28 条

[1]

Akopyan Z.I., Stesina L.N., Gorkin V.Z., New properties of highly purified bovine liver mitochondrial monoamine oxidase. Reversible oxidation of sulphydryl groups and reversible qualitative alteration (transformation) of substrate and inhibitor specificity, Journal of Biological Chemistry, 246, pp. 4610-4618, (1971)

[2]

Baumanis E.A., Birska I.A., Reikhman G.O., Shvedov V.I., Gorkin V.Z., On the mechanisms of modification by pirazidole of the catalytic activity of mitochondrial monoamine oxidase, Voprosy Meditsinskoi Khimii, 6, pp. 90-96, (1987)

[3]

Dvoryantseva G.G., Polshakov V.I., Sheinker Y.N., Shvedov V.I., Grinev A.N., Et al., Structure-activity relationships in pyrazino [3,2,1-j,k] carbazole derivatives. A new antidepressant, pirlindole, and related compounds, European Journal of Medicinal Chemistry, 20, pp. 414-418, (1985)

[4]

Gorkin V.Z., Monoamine oxidases: versatility of catalytic properties and possible biological functions, Advances in Pharmacology and Chemotherapy, 11, pp. 1-50, (1973)

[5]

Gorkin V.Z., Monoamine oxidase inhibitors and the transformation of monoamine oxidases, Monoamine oxidase and its inhibitors, pp. 61-81, (1976)

[6]

Gorkin V.Z., Enzyme transformations, Horizons in biochemistry and biophysics, pp. 1-35, (1977)

[7]

Gorkin V.Z., Amine oxidases in clinical research, (1983)

[8]

Gorkin V.Z., Studies on the nature and specific inhibition of monoamine oxidases, Neuropharmacology 1985, pp. 9-14, (1985)

[9]

Gorkin V.Z., Qualitative alteration (transformation) in catalytic activity of amine oxidases, Structure and functions of amine oxidases, pp. 205-208, (1985)

[10]

Gornall A.G., Bardawill C.J., David M., Determination of serum proteins by means of biuret reaction, Journal of Biological Chemistry, 177, pp. 751-766, (1949)

← 1 2 3 →